Atrial septal defect-associated pulmonary hypertension with decompensated heart failure: outcomes after fenestrated device closure
Cardiology in the Young · 2024
DOI: 10.1017/s104795112300152x ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiology in the Young, 2024. Verfasst von Ahmed Deniwar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Betz Congenital Heart Center, Helen DeVos Children's Hospital of Spectrum Health Hospital, Grand Rapids, MI, USA. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Pulmonary Arterial Hypertension, Heart Septal Defects, Atrial, Heart Failure. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Up to 90% of adults with untreated atrial septal defect will be symptomatic by 4 th decade, and 30-49% will develop heart failure. 8–10% of these patients have pulmonary arterial hypertension with a female predominance regardless of age. We aimed to demonstrate that fenestrated closure can be safely performed in patients with decompensated heart failure and atrial septal defect-associated pulmonary arterial hypertension with improved outcome.
Methods
Transcatheter fenestrated atrial septal defect closures (Occlutech GmbH, Jena, Germany) were performed on a compassionate-use basis in 5 consecutive adult patients with atrial septal defect-associated pulmonary arterial hypertension and severe heart failure with prohibitive surgical mortality risks. Change in systemic oxygen saturation, 6-minute walk test, NYHA class, echocardiographic and haemodynamic parameters were used as parameters of outcome.
Results
All patients were female, mean age 48.8 ± 13.5 years, followed up for a median of 29 months (max 64 months). Significant improvements observed in the 6-minute walk test, and oxygen saturation comparing day 0 time point to all other follow-up time points data ( B = 1.32, SE = 0.28, t (22.7) = -4.77, p = 0.0001); and in the haemodynamic data (including pulmonary vascular resistance and pulmonary pressure) ( B = –0.60, SE = 0.22, t (40.2) = 2.74, p = .009). All patients showed improved right ventricular size and function along with NYHA class. There were no procedure-related complications.
Conclusion
Fenestrated atrial septal defect closure is feasible in adults with decompensated heart failure and atrial septal defect-associated pulmonary arterial hypertension. It results in sustained haemodynamic and functional improvement
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Betz Congenital Heart Center, Helen DeVos Children's Hospital of Spectrum Health Hospital, Grand Rapids, MI, USA.
- Pediatrics and Human Development, Michigan State University College of Human Medicine, Grand Rapids, MI, USA.
ORCID-Profile: Ahmed Deniwar, Michael T Finn
Zitieren
APA
Deniwar, A., Hernandez, J., Aregullin, E. O., Khan, S. K., Huang, S., Finn, M. T., & Vettukattil, J. J. (2024). Atrial septal defect-associated pulmonary hypertension with decompensated heart failure: outcomes after fenestrated device closure. Cardiology in the Young. https://doi.org/10.1017/s104795112300152x
Vancouver
Deniwar A, Hernandez J, Aregullin EO, Khan SK, Huang S, Finn MT, et al. Atrial septal defect-associated pulmonary hypertension with decompensated heart failure: outcomes after fenestrated device closure. Cardiology in the Young. 2024. doi:10.1017/s104795112300152x
BibTeX
@article{Deniwar2024,
author = {Deniwar, Ahmed and Hernandez, Jason and Aregullin, Enrique O and Khan, Sana K and Huang, Sihong and Finn, Michael T and Vettukattil, Joseph J},
title = {Atrial septal defect-associated pulmonary hypertension with decompensated heart failure: outcomes after fenestrated device closure},
journal = {Cardiology in the Young},
year = {2024},
doi = {10.1017/s104795112300152x}
}
EUVIMED